In vivo and in vitro experiments demonstrated that ITGB2 was significantly upregulated in LPS‐induced cells and DSS‐treated tissues, and in vivo, siRNA of ITGB2 had therapeutic effects in an IBD mouse model. Here, ITGB2 is linked to inflammatory bowel disease.